RxDoctor Payments Data

Lincoln Hernandez, MD

Internal Medicine · New York, NYNPI 1932137106

Payments from drug & device makers

$1,006,027in general payments, 2019–2025

Across 294 payments — averaging $3421.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braintree Laboratories, Inc.$544K
  • GSK$252K
  • AbbVie$129K
  • Gilead$44K
  • Boehringer Ingelheim International GmbH$12K
  • AstraZeneca$12K
  • plus $13K from 17 others

What the payments were for

  • Consulting fees$120%
  • Speaking & faculty fees$37,94983%
  • Travel & lodging$4,2719%
  • Food & beverage$3,5058%
  • Education$1250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,006,027 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$15,467
Medicare patients
47
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab31$820,976
LinzessLinaclotide144$87,361
Humira PenAdalimumab13$82,934
RinvoqUpadacitinib13$78,253
XifaxanRifaximin14$32,228
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates250$12,894
CreonLipase/Protease/Amylase14$11,238
CholestyramineCholestyramine (With Sugar)81$7,439
Omeprazole522$3,978
Tenofovir Disoproxil Fumarate12$3,487
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl233$2,954
Dexlansoprazole DrDexlansoprazole20$2,952
Cholestyramine LightCholestyramine23$2,283
Famotidine129$1,058
Procto-Med HcHydrocortisone120$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$182$820,97631 claims
AbbVieLinzess, Rinvoq, Creon$129,340$176,851171 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$338$32,22814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →